Loading
institutionsInstitution
Centre hospitalier de l'Université de Montréal (CHUM)
The CHUM is the Université de Montréal's adult teaching hospital; Bertrand Routy's 2018 work here showed that gut bacteria shape response to checkpoint inhibitors, Fred Saad co-led prostate cancer trials such as PROpel, and it runs Quebec's largest oncology trial programme.
Also called: CHUMCRCHUM
Overview
The CHUM is the Université de Montréal's adult teaching hospital, consolidated on a new downtown campus in 2017, with the Centre de recherche du CHUM (CRCHUM) and the Institut du cancer de Montréal as its research arms. Bertrand Routy's 2018 Science paper showed that antibiotics blunt checkpoint inhibitor efficacy and that specific gut bacteria predict response, launching faecal microbiota transplant trials to overcome immunotherapy resistance. Urologist Fred Saad has led or co-led landmark prostate cancer trials, including PROpel (olaparib plus abiraterone), and Réjean Lapointe's group develops TIL and T-cell therapies. The hospital runs Quebec's largest oncology clinical trial programme in French and English.
Location
Montréal, QC, CA
Type
hospital · Université de Montréal
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#255 · 24 points (0 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Centre Hospitalier de l’Université de Montréal, including child institutions. 417 works · 6,369 citations · 71% open access · 13% clinical trials · 1% reviews.
Oncology works per year
812022
912023
782024
912025
762026
Most works
- Roupen Djinbachian39 works
- Fred Saad31 works
- Daniel von Renteln28 works
- Mustapha Ali Tehfe23 works
- Rahima Jamal23 works
- Diane Michele Provencher21 works
- Victoire Michal19 works
- Megan Oleksiw18 works
- Anne‐Marie Mes‐Masson17 works
- Bertrand Routy16 works
Most cited
- Microbiome and immunotherapy
- Prostate cancer trials
- T-cell immunotherapy
- Ovarian cancer biobanking
Fred Saad
Professor and Chief of Urology, Centre hospitalier de l'Université de Montréal
Advanced prostate cancerBone-targeted therapyAndrogen receptor inhibitors
Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.
Marie-Eve Desrosiers
Présidente-directrice générale of the CHUM
Hospital leadershipHealth system managementAcademic medicine
President and chief executive of the CHUM, the University of Montreal's teaching hospital and one of Canada's largest academic health centres.
Similar pages
- TrialMIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma
Shares Microbiome modulation to unlock immunotherapy, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
- TechnologyFaecal microbiota transplantation for PD-1 non-responders
Shares Microbiome modulation to unlock immunotherapy, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
- TechnologyProbiotics, antibiotics and stewardship around immunotherapy
Shares Microbiome modulation to unlock immunotherapy, No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors.
- TrialStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Shares Abiraterone acetate, Olaparib, Prostate cancer, Immune checkpoint inhibitors.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Melanoma, Immune checkpoint inhibitors.
- IdeaTreat immunotherapy side-effects without wiping out the response
Shares No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaTest protein and resistance training during immunotherapy
Shares No one can predict who responds to immunotherapy, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
cancers
technologies
drugs
ApprovedSmall-molecule CYP17A1 inhibitor
Abiraterone acetate · Zytiga (generic)
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza